Why patients receive treatments that are minimally effective?
Why patients receive treatments that are minimally effective?, Published online: 24 September 2018; doi:10.1038/s41571-018-0101-4The value of medical treatments is an issue that has been actively debated in recent years and is not unique to oncology. In this Comment, we discuss why we pursue treatments which might have limited benefit from the point of view of three parties: the patient, the physician, and the pharmaceutical industry. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 24, 2018 Category: Cancer & Oncology Authors: Christopher M. Booth Allan S. Detsky Source Type: research
Let’s address burnout in oncologists and reimagine the way we work
Let’s address burnout in oncologists and reimagine the way we work, Published online: 21 September 2018; doi:10.1038/s41571-018-0097-9Burnout is a substantial issue associated with the medical profession, with oncology being no exception. Increasing focus is being placed on implementing solutions to address physician burnout, and successful interventions have encompassed the following themes: the presence of an organizational mandate, data-driven and grassroots quality improvements, and a focus on systems change. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 21, 2018 Category: Cancer & Oncology Authors: Krithika Murali Susana Banerjee Source Type: research
Chemoprevention of Barrett’s oesophagus: a step closer with PPIs and aspirin
Chemoprevention of Barrett’s oesophagus: a step closer with PPIs and aspirin, Published online: 20 September 2018; doi:10.1038/s41571-018-0096-xChemoprevention for patients with Barrett’s oesophagus remains a controversial topic. Results of the first randomized trial of chemoprevention using a proton pump inhibitor with or without aspirin were recently reported. We highlight strengths and weaknesses in the design of the trial and discuss the clinical implications of the findings. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 20, 2018 Category: Cancer & Oncology Authors: Nisreen S. Husain Hashem B. El-Serag Source Type: research
Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy, Published online: 19 September 2018; doi:10.1038/s41571-018-0095-yIntriguing evidence suggests that expression of RANK or RANKL by various cells of the tumour microenvironment modulates the anticancer immune response. Herein, the authors review this evidence, discuss the current preclinical and clinical data supporting a potential of RANKL inhibition to improve anticancer immunotherapy and describe hypothetical immune-related mechanisms of action. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 19, 2018 Category: Cancer & Oncology Authors: Elizabeth Ahern Mark J. Smyth William C. Dougall Michele W. L. Teng Source Type: research
PD-1 mRNA predicts response to therapy
PD-1 mRNA predicts response to therapy, Published online: 14 September 2018; doi:10.1038/s41571-018-0100-5PD-1 mRNA predicts response to therapy (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 14, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Immunogenomic features of mCRPC revealed
Immunogenomic features of mCRPC revealed, Published online: 14 September 2018; doi:10.1038/s41571-018-0098-8Immunogenomic features of mCRPC revealed (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 14, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Erlotinib effective in the neoadjuvant setting
Erlotinib effective in the neoadjuvant setting, Published online: 14 September 2018; doi:10.1038/s41571-018-0099-7Erlotinib effective in the neoadjuvant setting (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 14, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Precision risk-based screening might maximize benefit and minimize harm
Precision risk-based screening might maximize benefit and minimize harm, Published online: 14 September 2018; doi:10.1038/s41571-018-0093-0Population-based mammographic screening is widely accepted as an intervention to reduce overall mortality from breast cancer, but at the cost of morbidity due to false positives and substantial overdiagnosis and overtreatment of ultra-low-risk disease, as well as personal and health-economic burdens. Recent data from a modelling study strengthen the rationale for personalized, risk-based screening approaches, now being tested in multiple clinical trials. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 14, 2018 Category: Cancer & Oncology Authors: Laura J. Esserman Andrea Z. LaCroix Source Type: research
Progress in adjuvant systemic therapy for breast cancer
Progress in adjuvant systemic therapy for breast cancer, Published online: 11 September 2018; doi:10.1038/s41571-018-0089-9Improvements in the management of patients with early stage breast cancer have been achieved through intense therapeutic escalation but also with de-escalation of systemic therapies. The authors of this Review summarize key trials using both approaches and highlight the need to use therapeutic escalation for patients who would benefit from that approach and de-escalation for patients with a favourable prognosis. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 11, 2018 Category: Cancer & Oncology Authors: Noam F. Pond é Dimitrios Zardavas Martine Piccart Source Type: research
What’s new under the Sun for ICIs?
What’s new under the Sun for ICIs?, Published online: 07 September 2018; doi:10.1038/s41571-018-0094-zWhat’s new under the Sun for ICIs? (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 7, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission
Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission, Published online: 04 September 2018; doi:10.1038/s41571-018-0087-yThe approval of blinatumomab based on achievement of undetectable minimal residual disease (MRD) in patients with B cell acute lymphoblastic leukaemia in complete remission is the first of its kind and raises important considerations. This drug might improve outcomes in this setting, although considerable evidence is needed to validate the performance of MRD as a surrogate end point and confirm the hypothesis. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 4, 2018 Category: Cancer & Oncology Authors: Talal Hilal Vinay Prasad Source Type: research
ctDNA predicts outcomes in DLBCL
ctDNA predicts outcomes in DLBCL, Published online: 03 September 2018; doi:10.1038/s41571-018-0091-2ctDNA predicts outcomes in DLBCL (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 3, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Mesothelioma risk genes revealed
Mesothelioma risk genes revealed, Published online: 03 September 2018; doi:10.1038/s41571-018-0092-1Mesothelioma risk genes revealed (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 3, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
EMBRACing a new PARP inhibitor?
EMBRACing a new PARP inhibitor?, Published online: 03 September 2018; doi:10.1038/s41571-018-0090-3EMBRACing a new PARP inhibitor? (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - September 3, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Signatures IMPRES and might turn the TIDE in predicting responses
Signatures IMPRES and might turn the TIDE in predicting responses, Published online: 31 August 2018; doi:10.1038/s41571-018-0088-xSignatures IMPRES and might turn the TIDE in predicting responses (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - August 31, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
